| 000 | 01897 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250517225853.0 | ||
| 264 | 0 | _c20190314 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1096-0333 | ||
| 024 | 7 |
_a10.1016/j.taap.2018.07.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLuangmonkong, Theerut | |
| 245 | 0 | 0 |
_aIn vitro and ex vivo anti-fibrotic effects of LY2109761, a small molecule inhibitor against TGF-β. _h[electronic resource] |
| 260 |
_bToxicology and applied pharmacology _c09 2018 |
||
| 300 |
_a127-137 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xmetabolism |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCell Line |
| 650 | 0 | 4 |
_aCollagen Type I _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDown-Regulation |
| 650 | 0 | 4 |
_aFibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aGene Expression _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aPyrazoles _xpharmacology |
| 650 | 0 | 4 |
_aPyrroles _xpharmacology |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aSmad1 Protein _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSmad2 Protein _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTissue Inhibitor of Metalloproteinase-2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aTransforming Growth Factor beta _xantagonists & inhibitors |
| 700 | 1 | _aSuriguga, Su | |
| 700 | 1 | _aAdhyatmika, Adhyatmika | |
| 700 | 1 | _aAdlia, Amirah | |
| 700 | 1 | _aOosterhuis, Dorenda | |
| 700 | 1 | _aSuthisisang, Chuthamanee | |
| 700 | 1 | _ade Jong, Koert P | |
| 700 | 1 | _aMutsaers, Henricus A M | |
| 700 | 1 | _aOlinga, Peter | |
| 773 | 0 |
_tToxicology and applied pharmacology _gvol. 355 _gp. 127-137 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.taap.2018.07.001 _zAvailable from publisher's website |
| 999 |
_c28632638 _d28632638 |
||